Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Chediak-Higashi syndrome 1 pseudogene** (ENSG00000235775) is a non-functional pseudogene related by sequence homology to the *LYST* gene, which encodes the lysosomal trafficking regulator protein. Chediak-Higashi syndrome (CHS) itself is a rare, autosomal recessive disorder caused by loss-of-function mutations in *LYST*, leading to defects in lysosome trafficking, oculocutaneous albinism, immune deficiency, and neurological dysfunction. The CHS1 pseudogene does not produce a functional protein and does not have known biological or clinical significance[1][7].\n\nKey clarification: \n- The biologically and clinically relevant gene in Chediak-Higashi syndrome is *LYST*, usually referred to as "lysosomal trafficking regulator". The pseudogene has no known role in disease mechanisms or diagnostics and is not a molecular target for therapy[1][7]. \n- If you are seeking information relevant to the disease or therapeutic intervention, you should refer to the functional *LYST* gene, not its pseudogene.\n\nIf "target" information is sought for drug discovery, *LYST* is the correct entity; this entry (ENSG00000235775) does not correspond to a molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chediak-Higashi syndrome 1 pseudogene.